Business Context and Reporting Period
Company: CollPlant Biotechnologies Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2022 (Specifically June 29, 2022)
Context: The filing incorporates a press release regarding the advancement of the company's 3D bioprinted regenerative breast implants into a porcine study.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves solely to disseminate a corporate press release and does not contain financial statements or quantitative financial data.
Material Changes
Operational Milestone: The company announced the progression of its 3D bioprinted regenerative breast implants into a porcine study. No financial material changes were reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release titled "CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study."
Forward-Looking Statements: The first paragraph and "Forward Looking Statements" section of the attached press release are incorporated by reference into the registrant's Registration Statements on Form S-8 and Form F-3.
Risks and Contingencies: Specific risks or contingencies are not detailed in the body of this Form 6-K; investors are directed to the incorporated press release for forward-looking information.
Key Facts for Investor Verification
- Verify the details and timeline of the porcine study for 3D bioprinted regenerative breast implants via the attached Exhibit 99.1 press release.
- Review the incorporated "Forward Looking Statements" in the press release for potential risks associated with the clinical study.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F for financial metrics.